Find a Product

BioMAP® Oncology and Immune Oncology Panels

    BioMAP Oncology and Immune Oncology PanelsSystems consist of complex co-cultures of PBMCs pooled from healthy donors with early passage human primary fibroblasts or endothelial cells, with or without a tumor cell line. These systems are stimulated to recapitulate and model tumor-immune-stromal, immune-stromal, tumor-immune-vascular or immune-vascular microenvironments and disease relevant signaling pathways that manifest during tumorigenesis. By measuring and analyzing biomarker activities and/or comparing the resulting activity profiles of a test agent to the profiles of selected reference compounds or drugs, one can gain insight into the mechanism of action, efficacy and safety-related effects.

View Systems

Drug Discovery Applications

  • Biological mechanism of action, efficacy and safety
  • Biomarker discovery
  • Benchmarking to clinical drug or reference compound
  • Testing of drug or compound combinations

Oncology and Immune Oncology Panel Advantages

  • PBMCs, human primary fibroblasts or endothelial cells, cancer cell lines
  • Microenvironment - immune, vascular or stromal, tumor
  • Additional custom protein biomarker readout options

Oncology and Immune Oncology Systems

Service

  • Test agent (chemical compound or biologic) profiling in selected BioMAP Systems
  • 4 concentrations in triplicate

Description

  • Annotation Identification and biological interpretation of relevant BioMAP biomarker activities (readouts)
  • Benchmarking Direct comparison of test agent to a specified clinical drug or reference compound from BioMAP database (list available upon request)

Deliverables

  • Study Report BioMAP profile plots, annotation of activities with respect to biological significance, graphical overlays of test agent and drug or reference compound profiles, expert data interpretation and analysis
  • Data Report Log ratio data tables, table of cytotoxicities, table of active readouts

CRC Systems & Biomaker Readouts

System ▲RelevanceCell TypeBiomarker Readout
StroHT29Host Stromal-Tumor Microenvironment, Oncology, Oncology - CRCHT-29 colon adenocarcinoma cell line + Peripheral blood mononuclear cells + Primary human fibroblastsCD106/VCAM-1, CD87/uPAR, CEACAM5/CD66e, Collagen I, Collagen III, CXCL10/IP-10, Keratin 20, MMP-9, PAI-I, PBMC Cytotoxicity, sGranzyme B, sIFN-γ, sIL-10, sIL-17A, sIL-2, sIL-6, SRB, sTNF-α, sVEGF, TIMP-2, tPA, uPA
VascHT29Host Vascular-Tumor Microenvironment, Oncology, Oncology - CRCHT-29 colon adenocarcinoma cell line + Peripheral blood mononuclear cells + Primary human endothelial cellsCCL2/MCP-1, CD106/VCAM-1, CD40, CD69, CD87/uPAR, CEACAM5/CD66e, Collagen IV, CXCL10/IP-10, CXCL9/MIG, Keratin 20, PBMC Cytotoxicity, sGranzyme B, sIFN-γ, sIL-10, sIL-17A, sIL-2, sIL-6, SRB, sTNF-α

NSCLC Systems & Biomaker Readouts*

(* Biomarker readouts in final development and subject to change. Please inquire.)
System ▲RelevanceCell TypeBiomarker Readout *
StroNSCLCHost Stromal-Tumor Microenvironment, Oncology, Oncology - NSCLCH1299 NSCLC cell line + Peripheral blood mononuclear cells + Primary human fibroblastsCD106/VCAM-1, CD87/uPAR, Collagen III, CXCL10/IP-10, EGFR, HGF, PAI-I, PBMC Cytotoxicity, sGranzyme B, sIFN-γ, sIL-10, sIL-13, sIL-17A, sIL-2, sIL-4, sIL-6, sMDC, sPGE2, SRB, sTNF-α, sVEGF, tPA, uPA
VascNSCLCHost Vascular-Tumor Microenvironment, Oncology, Oncology - NSCLCH1299 NSCLC cell line + Peripheral blood mononuclear cells + Primary human endothelial cellsCCL2/MCP-1, CD106/VCAM-1, CD40, CD69, CD87/uPAR, CXCL10/IP-10, PAI-I, PBMC Cytotoxicity, sGranzyme B, sIFN-γ, sIL-10, sIL-13, sIL-17A, sIL-2, sIL-4, sIL-6, sMDC, SRB, sTNF-α